A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid [aspirin] (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA

Trial Profile

A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid [aspirin] (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2009

At a glance

  • Drugs Aspirin; Aspirin/esomeprazole; Esomeprazole
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced gastrointestinal damage
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Jun 2009 Results were reported at Digestive Disease Week 2009.
    • 04 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top